FENNEC PHARMACEUTICALS INC (FRX.CA) Stock Fundamental Analysis
TSX:FRX - CA31447P1009 - Common Stock
12.33 CAD
-0.03 (-0.24%)
Taking everything into account, FRX scores 3 out of 10 in our fundamental rating. FRX was compared to 24 industry peers in the Biotechnology industry. The financial health of FRX is average, but there are quite some concerns on its profitability. FRX is valued correctly, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year FRX has reported negative net income.
In the past year FRX has reported a negative cash flow from operations.
FRX had negative earnings in each of the past 5 years.
FRX had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
With a decent Return On Assets value of -26.83%, FRX is doing good in the industry, outperforming 75.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -26.83% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-49.57%
ROA(5y)-56.75%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
FRX's Gross Margin of 89.89% is amongst the best of the industry. FRX outperforms 100.00% of its industry peers.
The Profit Margin and Operating Margin are not available for FRX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 89.89% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for FRX has been increased compared to 1 year ago.
FRX has more shares outstanding than it did 5 years ago.
The debt/assets ratio for FRX has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -3.24, we must say that FRX is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -3.24, FRX is in the better half of the industry, outperforming 70.83% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.24 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 4.85 indicates that FRX has no problem at all paying its short term obligations.
FRX has a Current ratio of 4.85. This is in the better half of the industry: FRX outperforms 75.00% of its industry peers.
A Quick Ratio of 4.59 indicates that FRX has no problem at all paying its short term obligations.
FRX has a Quick ratio of 4.59. This is in the better half of the industry: FRX outperforms 75.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.85 | ||
| Quick Ratio | 4.59 |
3. Growth
3.1 Past
The earnings per share for FRX have decreased strongly by -520.00% in the last year.
FRX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -31.89%.
EPS 1Y (TTM)-520%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45%
Revenue 1Y (TTM)-31.89%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%32.91%
3.2 Future
The Earnings Per Share is expected to grow by 240523.00% on average over the next years. This is a very strong growth
Based on estimates for the next years, FRX will show a very strong growth in Revenue. The Revenue will grow by 25.30% on average per year.
EPS Next Y169782103072165900%
EPS Next 2Y11530794814.79%
EPS Next 3Y28002300%
EPS Next 5Y240523%
Revenue Next Year-16.49%
Revenue Next 2Y12.56%
Revenue Next 3Y14.55%
Revenue Next 5Y25.3%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for FRX. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 12.12, the valuation of FRX can be described as correct.
Based on the Price/Forward Earnings ratio, FRX is valued cheaper than 95.83% of the companies in the same industry.
FRX is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 22.52, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 12.12 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
FRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as FRX's earnings are expected to grow with 28002300.00% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11530794814.79%
EPS Next 3Y28002300%
5. Dividend
5.1 Amount
No dividends for FRX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:FRX (9/2/2025, 7:00:00 PM)
12.33
-0.03 (-0.24%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners56.63%
Inst Owner ChangeN/A
Ins Owners1.93%
Ins Owner ChangeN/A
Market Cap343.14M
Analysts85.45
Price Target19.51 (58.23%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-71.86%
Min EPS beat(2)-199.56%
Max EPS beat(2)55.84%
EPS beat(4)1
Avg EPS beat(4)-101.98%
Min EPS beat(4)-199.56%
Max EPS beat(4)55.84%
EPS beat(8)3
Avg EPS beat(8)-153.59%
EPS beat(12)4
Avg EPS beat(12)-110.94%
EPS beat(16)6
Avg EPS beat(16)-92.6%
Revenue beat(2)1
Avg Revenue beat(2)2.15%
Min Revenue beat(2)-0.57%
Max Revenue beat(2)4.87%
Revenue beat(4)1
Avg Revenue beat(4)-18.28%
Min Revenue beat(4)-53.52%
Max Revenue beat(4)4.87%
Revenue beat(8)4
Avg Revenue beat(8)-6.65%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)11.54%
PT rev (3m)-2.63%
EPS NQ rev (1m)-30%
EPS NQ rev (3m)-52.54%
EPS NY rev (1m)-45%
EPS NY rev (3m)-9.94%
Revenue NQ rev (1m)0.82%
Revenue NQ rev (3m)-20.49%
Revenue NY rev (1m)0.11%
Revenue NY rev (3m)2.37%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 12.12 | ||
| P/S | 7.47 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.58
EYN/A
EPS(NY)1.02
Fwd EY8.25%
FCF(TTM)-0.6
FCFYN/A
OCF(TTM)-0.6
OCFYN/A
SpS1.65
BVpS-0.37
TBVpS-0.37
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -26.83% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 89.89% | ||
| FCFM | N/A |
ROA(3y)-49.57%
ROA(5y)-56.75%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.74
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.85 | ||
| Quick Ratio | 4.59 | ||
| Altman-Z | -3.24 |
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-520%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45%
EPS Next Y169782103072165900%
EPS Next 2Y11530794814.79%
EPS Next 3Y28002300%
EPS Next 5Y240523%
Revenue 1Y (TTM)-31.89%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%32.91%
Revenue Next Year-16.49%
Revenue Next 2Y12.56%
Revenue Next 3Y14.55%
Revenue Next 5Y25.3%
EBIT growth 1Y-258.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year2876.34%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y43.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y43.63%
OCF growth 3YN/A
OCF growth 5YN/A